Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
about
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolongBiologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic TrendHematopoietic stem cell transplantation for auto immune rheumatic diseasesTreatment of juvenile idiopathic arthritis: a revolution in careThe lived experience of juvenile idiopathic arthritis in young people receiving etanercept.IL-1 Inhibition in Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentEffectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.Intravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: an innovative clinical research approach.Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of ChildrEtanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis.Pharmacotherapy for uveitis: current management and emerging therapy.A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitorA multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Etanercept biosimilarsThe development and assessment of biological treatments for children.Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis.Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidityThe German etanercept registry for treatment of juvenile idiopathic arthritis.Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Diagnosis and management of adult onset Still's disease.Systemic arthritis in children: a review of clinical presentation and treatmentAdalimumab in the therapy of uveitis in childhoodIs Still's Disease an Autoinflammatory Syndrome?Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationBiological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade.Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.Juvenile idiopathic arthritis: current and future treatment options.Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.TNFalpha blockade in human diseases: an overview of efficacy and safety.Etanercept treatment in juvenile idiopathic arthritis: the Polish registryFactors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept CohortInfluence of biologic therapy on growth in children with chronic inflammatory connective tissue diseasesEtanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.
P2860
Q24812856-F9862D7B-46B7-4124-8AB1-642E72B12F8BQ26741357-E7B4AD18-A3A5-49F5-B15F-D045AF8E6654Q26751425-6DCE41A5-D0DE-4646-ACC9-EDC520D818F5Q26849497-C9DF100A-1BA1-4174-9E12-16ABD3DD7D80Q27303519-160D23A3-FB4E-4D22-B0D7-5F824F9A2463Q28078134-F218B2EF-50DA-4E87-B65C-64C32A050ED2Q28079246-F3394770-FC75-46E2-8212-7E90E051DDEFQ31032345-66EE0DBB-1471-477A-9056-3F4D83753772Q31130038-C0B5FA26-1378-4458-9432-3737DE826FCCQ33401933-E6AAB308-1246-4BD7-A713-9C23D3B67020Q33636807-9BA36254-0BEA-40BF-8667-3315A19A6E29Q33801499-357EFBD3-4696-4EEA-85AE-1CFAC518C953Q33804799-1C7B8708-C153-4C9A-A206-20FB77425A82Q34063418-00DEAE6F-F352-44A6-9ECA-58EAD337D9C8Q34274075-9B91BC2A-7609-4198-88FF-4A150D2F714DQ34632661-E042FE2F-6F1C-4DD0-B91A-D9D690C2AABDQ34709566-636346E4-CDA8-436B-8AF2-6FBD12757DCCQ34758768-47A00D5C-5DC8-4602-8DD9-B400C7D06B06Q35020358-4ECBC413-2C03-4054-8817-521C54B4DE64Q35135936-4D0854DD-F4AF-445F-97BE-BCCCB6D3B357Q35194346-BB17C3B6-3F93-4E95-A26F-8414679ABE3EQ35553325-046553C2-E47F-40B8-8541-2DC35BE4B170Q35553680-D5443EAE-1503-4BED-BD03-4DC87A9D615AQ35555818-4120457C-9F8E-4373-B797-CCB362E18B5EQ35567870-770A0F60-B9D1-4189-A0D7-2FB92ABD045CQ35637158-6C1AA00F-549E-4430-8370-8886622FBAD4Q35659928-813103D1-E23D-4BF8-87F0-95CAA004DDDEQ35763157-5419C894-8F3D-4275-9F0B-731476506910Q35955190-AF3F0F2D-E0F4-4405-990D-59E2900F804BQ36020897-5A677833-BAC0-45BF-AD1E-1DA360490262Q36183846-26338A0A-35C2-4CCB-BB6E-E754A05991D6Q36229664-F3F0E467-DC0E-434A-BE15-941898F33453Q36403583-E3E3690B-F02B-4490-B5E1-293673D9DE1EQ36407354-FD6C72E8-5CF7-4237-8660-E3D8804CF418Q36502928-C533442A-B53A-4810-9574-EFC55BDBAEB9Q36536861-7AC09458-EEA4-4FB8-ADA2-094B2FCA5B2AQ36771435-15EF71D3-9BA2-4B3E-BA74-31D97983180BQ36795982-F240F566-39B6-4857-8F43-CC727F9F6D97Q36842452-214CE2E5-A77B-496E-90A3-C444052036E1Q36847326-EE563B44-0B6D-49F1-8CCE-282627D777BE
P2860
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Efficacy of etanercept for the ...... s according to the onset type.
@en
Efficacy of etanercept for the ...... s according to the onset type.
@nl
type
label
Efficacy of etanercept for the ...... s according to the onset type.
@en
Efficacy of etanercept for the ...... s according to the onset type.
@nl
prefLabel
Efficacy of etanercept for the ...... s according to the onset type.
@en
Efficacy of etanercept for the ...... s according to the onset type.
@nl
P2093
P50
P356
P1476
Efficacy of etanercept for the ...... s according to the onset type.
@en
P2093
Anne-Marie Prieur
Brigitte Bader-Meunier
Irène Lemelle
Jean Sibilia
Marc LeBideau
Michel Bost
Pascal Pillet
Paul Landais
Pierre Taupin
Richard Mouy
P304
P356
10.1002/ART.10885
P577
2003-04-01T00:00:00Z